Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease

• Main Authors: Seiichi Hayato (Author), Osamu Takenaka (Author), Sree Harsha Sreerama Reddy (Author), Ishani Landry (Author), Larisa Reyderman (Author), Akihiko Koyama (Author), Chad Swanson (Author), Sanae Yasuda (Author), Ziad Hussein (Author)
• Format: Book
• Published: Wiley, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Lecanemab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to soluble Aβ aggregate species, while demonstrating low affinity for Aβ monomer. This article describes the population pharmacokinetic (PK) and PK/pharmacodynamic (PD) analyses for amyloid plaques, as mea...